Q2 EPS Estimates for Cytokinetics Raised by HC Wainwright

Cytokinetics, Incorporated (NASDAQ:CYTK) – Equities research analysts at HC Wainwright boosted their Q2 2026 earnings estimates for shares of Cytokinetics in a research note issued on Monday, May 11th. HC Wainwright analyst J. Pantginis now forecasts that the biopharmaceutical company will post earnings per share of ($1.53) for the quarter, up from their prior forecast of ($1.61). HC Wainwright has a “Buy” rating and a $140.00 price objective on the stock. The consensus estimate for Cytokinetics’ current full-year earnings is ($6.33) per share. HC Wainwright also issued estimates for Cytokinetics’ Q3 2026 earnings at ($1.80) EPS, Q4 2026 earnings at ($1.86) EPS, FY2026 earnings at ($6.86) EPS, FY2027 earnings at ($5.43) EPS and FY2028 earnings at ($2.08) EPS.

A number of other research analysts have also recently issued reports on CYTK. Leerink Partners reissued an “outperform” rating on shares of Cytokinetics in a research report on Tuesday, March 10th. Truist Financial set a $106.00 price target on shares of Cytokinetics in a research report on Tuesday, May 5th. Barclays lifted their price target on shares of Cytokinetics from $87.00 to $95.00 and gave the company an “overweight” rating in a research report on Monday, April 6th. Bank of America reaffirmed a “neutral” rating on shares of Cytokinetics in a report on Wednesday, February 25th. Finally, Royal Bank Of Canada lifted their target price on shares of Cytokinetics from $101.00 to $119.00 and gave the stock an “outperform” rating in a report on Wednesday, May 6th. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $98.55.

Cytokinetics Stock Up 0.3%

NASDAQ CYTK opened at $74.81 on Wednesday. Cytokinetics has a twelve month low of $29.31 and a twelve month high of $80.20. The firm has a market capitalization of $9.31 billion, a PE ratio of -10.94 and a beta of 0.38. The stock’s 50 day moving average is $64.98 and its 200 day moving average is $64.24.

Cytokinetics (NASDAQ:CYTK) last announced its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported ($1.67) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($1.67). The firm had revenue of $19.36 million during the quarter, compared to the consensus estimate of $8.52 million. During the same period last year, the business earned ($1.36) EPS. Cytokinetics’s revenue was up 1112.5% on a year-over-year basis.

Insider Buying and Selling at Cytokinetics

In other Cytokinetics news, EVP Andrew Callos sold 26,000 shares of the stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $61.87, for a total transaction of $1,608,620.00. Following the transaction, the executive vice president directly owned 50,440 shares in the company, valued at $3,120,722.80. This represents a 34.01% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Robert I. Blum sold 36,601 shares of the business’s stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $62.15, for a total transaction of $2,274,752.15. Following the completion of the transaction, the chief executive officer owned 430,330 shares of the company’s stock, valued at approximately $26,745,009.50. This represents a 7.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 169,976 shares of company stock worth $10,710,369 over the last 90 days. 2.60% of the stock is owned by insiders.

Institutional Trading of Cytokinetics

A number of large investors have recently made changes to their positions in the company. Kemnay Advisory Services Inc. acquired a new stake in shares of Cytokinetics during the fourth quarter worth $27,000. Kestra Advisory Services LLC bought a new position in Cytokinetics during the 4th quarter worth $29,000. TD Waterhouse Canada Inc. purchased a new stake in shares of Cytokinetics during the fourth quarter valued at $32,000. Northwestern Mutual Wealth Management Co. raised its stake in shares of Cytokinetics by 46.0% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 543 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 171 shares in the last quarter. Finally, Quarry LP bought a new position in Cytokinetics in the 3rd quarter worth approximately $30,000.

Cytokinetics Company Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.